Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.72 |
| ▸ | ACE | P12821 | 7/20 | 0.59 |
| ▸ | MME | P08473 | 6/20 | 0.59 |
| ▸ | CPA1 | P15085 | 2/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15223611 | 0.88 | MME (0.74) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL9822809 | 0.86 | FOLH1 (0.69) | FOLH1ACEMME | |
| SCHEMBL14940816 | 0.86 | FOLH1 (0.69) | FOLH1ACEMME | |
| SCHEMBL29532240 | 0.86 | FOLH1 (0.69) | FOLH1ACEMME | |
| Hydrochloric Acid SCHEMBL30698091 | 0.85 | FOLH1 (0.67) | FOLH1ACEMME | |
| SCHEMBL19432689 | 0.84 | FOLH1 (0.67) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL29477112 | 0.84 | FOLH1 (0.66) | FOLH1ACEMME | |
| SCHEMBL30538841 | 0.84 | FOLH1 (0.70) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL29531738 | 0.84 | FOLH1 (0.66) | FOLH1ACEMME | |
| SCHEMBL30683246 | 0.84 | FOLH1 (0.66) | FOLH1ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434762-B2 | Macrocyclic cysteine protease inhibitors and compositions thereof | UNIVERSITY OF CANTERBURY (NZ) | 2016-09-06 | — | — | US | disclosed |
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | LINCOLN UNIVERSITY (NZ) | 2014-07-10 | — | — | US | disclosed |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | UNIVERSITY OF CANTERBURY (NZ) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194362-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | FOLH1 803/4885ACE 68/4885MME 329/4885 |
| US-20110021434-A1 | Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof | CAPNS1, CAPN1, CAPN9 | FOLH1 803/4885ACE 68/4885MME 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.